PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Signal transducer and activator of transcription 5 (STAT5) is a key signaling node in hematological malignancies, often activated by the BCR-ABL oncogene.
• STAT5 is phosphorylated at tyrosine and serine residues (S725, S779), with serine phosphorylation's role in leukemogenesis under investigation.

Purpose of the Study:

• To investigate the significance of STAT5 serine phosphorylation in BCR-ABL-induced leukemogenesis.
• To identify the kinase responsible for STAT5 serine phosphorylation and its implications for therapeutic targeting.

Main Methods:

• Utilized a STAT5 mutant lacking S725 and S779 phosphorylation sites (STAT5(SASA)) in cultured bone marrow cells.
• Assessed leukemic potential in vivo using STAT5(SASA) BCR-ABL(+) cells.
• Investigated the role of p21-activated kinase (PAK) in STAT5 S779 phosphorylation.
• Examined the effect of BCR-ABL tyrosine kinase inhibitors on PAK-dependent STAT5 phosphorylation.

Main Results:

• Expression of STAT5(SASA) inhibited BCR-ABL-induced transformation and induced apoptosis in cultured cells.
• STAT5(SASA) BCR-ABL(+) cells exhibited significantly reduced leukemic potential in vivo.
• Loss of S779 phosphorylation was identified as the primary cause for reduced leukemic potential, preventing STAT5 nuclear translocation.
• Evidence suggests group I p21-activated kinase (PAK) phosphorylates STAT5 at S779.
• PAK-dependent STAT5 serine phosphorylation remained unaffected by BCR-ABL tyrosine kinase inhibitors.

Conclusions:

• STAT5 serine phosphorylation, especially S779, is essential for BCR-ABL-induced leukemogenesis.
• PAK-mediated phosphorylation of STAT5 at S779 is critical for its nuclear translocation and leukemic function.
• Targeting STAT5 phosphorylation, independent of BCR-ABL tyrosine kinase activity, presents a novel therapeutic avenue for BCR-ABL-induced malignancies.